<?xml version="1.0" encoding="UTF-8"?>
<p id="Par99" class="p">In an illness with a complex pathogenesis like Chagas Disease (which involves the parasitic persistence that triggers and sustains an anti-inflammatory immune response), the use of synergic drugs (like limonene/caryophyllene oxide) with several biological advantages (significant trypanocidal activity [
 <xref ref-type="bibr" rid="CR32" class="xref">32</xref>], low toxicity on mammal tissues [
 <xref ref-type="bibr" rid="CR53" class="xref">53</xref>]; and anti-genotoxic [
 <xref ref-type="bibr" rid="CR68" class="xref">68</xref>], chemoprotective [
 <xref ref-type="bibr" rid="CR23" class="xref">23</xref>], and anti-inflammatory activity [
 <xref ref-type="bibr" rid="CR22" class="xref">22</xref>]) could be an interesting platform for the development of an adjuvant therapy that enhances the therapeutic effects of the conventional treatments, principally in advanced stage of the infection (probably improving trypanocidal action, reducing therapeutic doses, increasing tolerance, or retarding resistance development) [
 <xref ref-type="bibr" rid="CR69" class="xref">69</xref>].
</p>
